Predicted Impact of Mass Drug Administration on the Development of Protective Immunity against Schistosoma haematobium

PLoS Neglected Tropical Diseases

Volumn 8, Issue 7, 2014, Pages

  Mitchell, Kate M ^a,e   Mutapi, Francisca ^a   Mduluza, Takafira ^b,c   Midzi, Nicholas ^b,d   Savill, Nicholas J ^a   Woolhouse, Mark E J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d NATIONAL INSTITUTE OF HEALTH RESEARCH   (Zimbabwe)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARASITE ANTIBODY; PARASITE ANTIGEN; PRAZIQUANTEL; ANTHELMINTIC AGENT; HELMINTH ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; EGG OUTPUT; HOST PARASITE INTERACTION; HUMAN; IMMUNE SYSTEM DECAY; IMMUNITY; IMMUNOSTIMULATION; INFECTION RATE; MORBIDITY; NONHUMAN; PARASITE IDENTIFICATION; PARASITE TRANSMISSION; POPULATION DYNAMICS; REPEATED DRUG DOSE; RISK REDUCTION; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS HAEMATOBIA; WORM EGG; ANIMAL; BLOOD; DRUG EFFECTS; DRUG THERAPY; IMMUNOLOGY; INFANT; INFORMATION PROCESSING; NEWBORN; PRESCHOOL CHILD; PROCEDURES; SCHISTOSOMA HAEMATOBIUM; TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTHELMINTICS; ANTIBODIES, HELMINTH; CHILD; CHILD, PRESCHOOL; DATA COLLECTION; DRUG THERAPY; HUMANS; INFANT; INFANT, NEWBORN; PARASITE EGG COUNT; PRAZIQUANTEL; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMIASIS HAEMATOBIA; YOUNG ADULT;

EID: 84905483165     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003059     Document Type: Article

References (48)

1. van der Werf MJ, de Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD, et al. (2003) Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 86: 125-139.
2. Gryseels B, Polman K, Clerinx J, Kestens L, (2006) Human schistosomiasis. Lancet 368: 1106-1118.
3. Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, et al. (2009) The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology 136: 1719-1730.
4. WHO (2006) Preventive chemotherapy in human helminthiasis. Geneva: WHO Press.
5. King CH, Muchiri E, Ouma JH, Koech D, (1991) Chemotherapy-based control of schistosomiasis haematobia. IV. Impact of repeated annual chemotherapy on prevalence and intensity of Schistosoma haematobium infection in an endemic area of Kenya. Am J Trop Med Hyg 45: 498-508.
6. Stothard JR, French MD, Khamis IS, Basáñez M-G, Rollinson D, (2009) The epidemiology and control of urinary schistosomiasis and soil-transmitted helminthiasis in schoolchildren on Unguja Island, Zanzibar. Trans R Soc Trop Med Hyg 103: 1031-1044.
7. French MD, Churcher TS, Gambhir M, Fenwick A, Webster JP, et al. (2010) Observed reductions in Schistosoma mansoni transmission from large-scale administration of praziquantel in Uganda: a mathematical modelling study. PLoS Negl Trop Dis 4: e897.
8. Chan MS, Nsowah-Nuamah NNN, Adjei S, Wen ST, Hall A, et al. (1998) Predicting the impact of school-based treatment for urinary schistosomiasis given by the Ghana Partnership for Child Development. Trans R Soc Trop Med Hyg 92: 386-389.
9. Wang X, Gurarie D, Mungai PL, Muchiri EM, Kitron U, et al. (2012) Projecting the long-term impact of school- or community-based mass-treatment interventions for control of Schistosoma infection. PLoS Negl Trop Dis 6: e1903.
10. Chan MS, Anderson RM, Medley GF, Bundy DAP, (1996) Dynamic aspects of morbidity and acquired immunity in schistosomiasis control. Acta Trop 62: 105-117.
11. Anderson RM, Medley GF, (1985) Community control of helminth infections of man by mass and selective chemotherapy. Parasitology 90: 629-660.
12. Kabatereine NB, Vennervald BJ, Ouma JH, Kemijumbi J, Butterworth AE, et al. (1999) Adult resistance to schistosomiasis mansoni: age-dependence of reinfection remains constant in communities with diverse exposure patterns. Parasitology 118: 101-105.
13. Etard JF, Audibert M, Dabo A, (1995) Age-acquired resistance and predisposition to reinfection with Schistosoma haematobium after treatment with praziquantel in Mali. Am J Trop Med Hyg 52: 549-558.
14. Woolhouse MEJ, (1998) Patterns in parasite epidemiology: the peak shift. Parasitol Today 14: 428-434.
15. Mutapi F, Ndhlovu PD, Hagan P, Woolhouse MEJ, (1997) A comparison of humoral responses to Schistosoma haematobium in areas with low and high levels of infection. Parasite Immunol 19: 255-263.
16. Pinot de Moira A, Fulford AJC, Kabatereine NB, Ouma JH, Booth M, et al. (2010) Analysis of Complex Patterns of Human Exposure and Immunity to Schistosomiasis mansoni: The Influence of Age, Sex, Ethnicity and IgE. PLoS Negl Trop Dis 4: e820.
17. Black CL, Mwinzi PN, Muok EM, Abudho B, Fitzsimmons CM, et al. (2010) Influence of exposure history on the immunology and development of resistance to human Schistosomiasis mansoni. PLoS Negl Trop Dis 4: e637.
18. Fitzsimmons CM, McBeath R, Joseph S, Jones FM, Walter K, et al. (2007) Factors affecting human IgE and IgG responses to allergen-like Schistosoma mansoni antigens: molecular structure and patterns of in vivo exposure. Int Arch Allergy Imm 142: 40-50.
19. Mutapi F, Ndhlovu PD, Hagan P, Woolhouse MEJ, (1998) Changes in specific anti-egg antibody levels following treatment with praziquantel for Schistosoma haematobium infection in children. Parasite Immunol 20: 595-600.
20. Satti MZ, Lind P, Vennervald BJ, Sulaiman SM, Daffalla AA, et al. (1996) Specific immunoglobulin measurements related to exposure and resistance to Schistosoma mansoni infection in Sudanese canal cleaners. Clin Exp Immunol 106: 45-54.
21. Grogan JL, Kremsner PG, vanDam GJ, Metzger W, Mordmuller B, et al. (1996) Antischistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults. J Infect Dis 173: 1242-1247.
22. Mutapi F, Ndhlovu PD, Hagan P, Spicer JT, Mduluza T, et al. (1998) Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. J Infect Dis 178: 289-293.
23. Mutapi F, Burchmore R, Mduluza T, Foucher A, Harcus Y, et al. (2005) Praziquantel treatment of individuals exposed to Schistosoma haematobium enhances serological recognition of defined parasite antigens. J Infect Dis 192: 1108-1118.
24. Dunne DW, Butterworth AE, Fulford AJ, Kariuki HC, Langley JG, et al. (1992) Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 22: 1483-1494.
25. Medhat A, Shehata M, Bucci K, Mohamed S, Dief ADE, et al. (1998) Increased interleukin-4 and interleukin-5 production in response to Schistosoma haematobium adult worm antigens correlates with lack of reinfection after treatment. J Infect Dis 178: 512-519.
26. Bourke CD, Nausch N, Rujeni N, Appleby LJ, Mitchell KM, et al. (2013) Integrated analysis of innate, Th1, Th2, Th17, and regulatory cytokines identifies changes in immune polarisation following treatment of human schistosomiasis. J Infect Dis 208: 159-169.
27. Black CL, Muok EMO, Mwinzi PNM, Carter JM, Karanja DMS, et al. (2010) Increases in levels of schistosome-specific immunoglobulin E and CD23+ B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni. J Infect Dis 202: 399-405.
28. Mitchell KM, Mutapi F, Savill NJ, Woolhouse MEJ, (2012) Protective immunity to Schistosoma haematobium infection is primarily an anti-fecundity response stimulated by the death of adult worms. Proc Natl Acad Sci U S A 109: 13347-13352.
29. Basáñez M-G, French MD, Walker M, Churcher TS, (2012) Paradigm lost: how parasite control may alter pattern and process in human helminthiases. Trends Parasitol 28: 161-171.
30. Chan MS, Mutapi F, Woolhouse MEJ, Isham VS, (2000) Stochastic simulation and the detection of immunity to schistosome infections. Parasitology 120: 161-169.
31. Woolhouse MEJ, Etard JF, Dietz K, Ndhlovu PD, Chandiwana SK, (1998) Heterogeneities in schistosome transmission dynamics and control. Parasitology 117: 475-482.
32. Mitchell KM, Mutapi F, Savill NJ, Woolhouse MEJ, (2011) Explaining observed infection and antibody age-profiles in populations with urogenital schistosomiasis. Plos Comput Biol 7: e1002237 doi:10.1371/journal.pcbi.1002237.
33. Amanna IJ, Carlson NE, Slifka MK, (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357: 1903-1915.
34. Macallan DC, Wallace DL, Zhang Y, Ghattas H, Asquith B, et al. (2005) B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood 105: 3633-3640.
35. Boulanger D, Warter A, Sellin B, Lindner V, Pierce RJ, et al. (1999) Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with an homologous challenge. Vaccine 17: 319-326.
36. Tohon ZB, Mainassara HB, Garba A, Mahamane AE, Bosqué-Oliva E, et al. (2008) Controlling schistosomiasis: significant decrease of anaemia prevalence one year after a single dose of praziquantel in Nigerien schoolchildren. PLoS Negl Trop Dis 2: e241.
37. WHO (2001) Schistosomiasis and soil transmitted helminth infections. Fifty fourth World Health Assembly, resolution WHA54.19 http://www.who.int/neglected_diseases/mediacentre/WHA_54.19_Eng.pdf (accessed 25/06/14).
38. Gabrielli A-F, Touré S, Sellin B, Sellin E, Ky C, et al. (2006) A combined school- and community-based campaign targeting all school-age children of Burkina Faso against schistosomiasis and soil-transmitted helminthiasis: Performance, financial costs and implications for sustainability. Acta Trop 99: 234-242.
39. Kabatereine NB, Tukahebwa E, Kazibwe F, Namwangye H, Zaramba S, et al. (2006) Progress towards countrywide control of schistosomiasis and soil-transmitted helminthiasis in Uganda. Trans R Soc Trop Med Hyg 100: 208-215.
40. Danso-Appiah A, Utzinger J, Liu J, Olliaro P (2008) Drugs for treating urinary schistosomiasis. Cochrane Database of Systematic Reviews: John Wiley & Sons, Ltd.
41. Schistosomiasis Control Initiative. http://www3.imperial.ac.uk/schisto (accessed 25/06/14).
42. Evengard B, Hammarstrom L, Smith CI, Johansson SG, Linder E, (1988) Subclass distribution and IgE responses after treatment in human schistosomiasis. Clin Exp Immunol 73: 383-388.
43. Vendrame CM, Carvalho MD, Yamamoto CR, Nakhle MC, Carvalho SA, et al. (2001) Evaluation of anti-Schistosoma mansoni IgG antibodies in patients with chronic schistosomiasis mansoni before and after specific treatment. Rev Inst Med Trop Sao Paulo 43: 153-159.
44. Williams GM, Sleigh AC, Li Y, Feng Z, Davis GM, et al. (2002) Mathematical modelling of schistosomiasis japonica: comparison of control strategies in the People's Republic of China. Acta Trop 82: 253-262.
45. Gurarie D, King CH, (2005) Heterogeneous model of schistosomiasis transmission and long-term control: the combined influence of spatial variation and age-dependent factors on optimal allocation of drug therapy. Parasitology 130: 49-65.
46. Spiegel JM, Dharamsi S, Wasan KM, Yassi A, Singer B, et al. (2010) Which new approaches to tackling neglected tropical diseases show promise? PLoS Med 7: e1000255.
47. Asaolu SO, Ofoezie IE, (2003) The role of health education and sanitation in the control of helminth infections. Acta Trop 86: 283-294.
48. World Health Assembly (2012) Resolution 65.21: Elimination of schistosomiasis. http://www.who.int/neglected_diseases/mediacentre/WHA_65.21_Eng.pdf (accessed 25/06/14).